| DIETHYLPROPION HYDROCHLORIDE
Nobesine , Propion, Ten-Tab, Tenuate, Tenuate Dospan, Tepanil
Classifications: anorexiant; Therapeutic: anorexiant
Pregnancy Category: B
Controlled Substance: Schedule IV
25 mg tablets; 75 mg sustained release tablets
Sympathomimetic amine chemically related to amphetamine. Has lower incidence of amphetamine-type adverse effects but reportedly
is less effective as an appetite suppressant. Anorexigenic action probably secondary to direct (CNS) stimulation of appetite
control center in hypothalamus and limbic regions. Also produces mild psychic stimulation and vasopressor effects.
Suppresses appetite as a result of drug action on CNS appetite control center.
Used solely in management of exogenous obesity as short-term (a few weeks) adjunct in a regimen of weight reduction based
on caloric restriction.
Known hypersensitivity or idiosyncrasy to sympathomimetic amines; severe hypertension, advanced arteriosclerosis, valvular
heart disease; hyperthyroidism; glaucoma; history of drug abuse; anorexia nervosa; symptomatic cardiovascular disease, arrhythmias;
MAOI therapy; pulmonary hypertension; children <6 y.
Hypertension, psychosis, mania, agitated states, epilepsy; diabetes mellitus; elderly, renal failure or impairment; seizure
disorder; pregnancy (category B), lactation.
Route & Dosage
Adult: PO 25 mg t.i.d. 3060 min a.c. or 75 mg sustained release q.d. midmorning
- Give on an empty stomach, ?1 h before meals.
- Note: Additional dose sometimes prescribed in midevening to control nighttime hunger. Rarely causes insomnia except in high doses.
- Titrate dosage carefully in patients with diabetes.
- Store between 15°30° C (59°86° F) in well-closed container unless otherwise specified.
Adverse Effects (≥1%)Body as a Whole:
Hypersensitivity (urticaria, rash, erythema); muscle pain, dyspnea, hair loss, blurred vision, severe dermatoses (chronic
intoxication), increased sweating. CNS:
Mild euphoria, restlessness, nervousness,
dizziness, headache, irritability, hyperactivity, insomnia
, drowsiness, mood changes, lethargy, increase in convulsive
episodes in patients with epilepsy
Palpitation, tachycardia, precordial pain, rise in BP. GI:
Nausea, vomiting, diarrhea, constipation
, dry mouth, unpleasant taste. Urogenital:
Impotence, changes in libido, gynecomastia, menstrual irregularities; polyuria, dysuria.
InteractionsDrug: Acetazolamide, sodium bicarbonate
decreases diethylpropion elimination; ammonium chloride, ascorbic acid
increases diethylpropion elimination; a barbiturate
and diethylpropion taken together may antagonize the effects of both drugs; furazolidone
may increase blood pressure effects of amphetamines
, and interaction may persist for several weeks after discontinuation of furazolidone; guanethidine
antagonizes antihypertensive effects; mao inhibitors
can cause hypertensive crisis (fatalities reported)amphetamines
should not be administered at the same time as or within 14 days of these drugs; phenothiazines
may inhibit mood elevating effects of amphetamines
; tricyclic antidepressants
effects by increasing norepinephrine
release; beta agonists
increase cardiovascular adverse effects.
Readily from GI tract. Duration:
4 h, regular tablets; 1014 h, sustained release. Elimination:
In urine. Half-Life:
Assessment & Drug Effects
- Observe patients with epilepsy closely for reduction in seizure control.
- Anorexigenic effect seldom lasts more than a few weeks. Discontinue if tolerance develops.
- Note: Varying degrees of psychologic and rarely physical dependence can occur.
Patient & Family Education
- Swallow sustained release tablets whole; do NOT chew.
- Do not drive or engage in other potentially hazardous activities until reaction to drug is known.